Negma Group has converted 120 convertible bonds in Oxurion resulting in a EUR 300,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
See the article here:
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
Recommendation and review posted by G. Smith
